Exelixis EXEL
NASDAQ EXEL
$58.39 +0.45 (+0.78%)
At close: Oct 2, 2026 · 4:00 PM EDT

Exelixis (EXEL) Gains from Sales and Divestitures (2011 - 2016)

Updated

Exelixis (EXEL) reported Gains from Sales and Divestitures of $2.49 million for Q3 2016.

Analysis

Exelixis (EXEL) Gains from Sales and Divestitures (2011 - 2016) Analysis & Trends

Over the twelve months ended Sep 30, 2016, Exelixis' Gains from Sales and Divestitures came in at $2.51 million; for FY2015, it was $112,000, down 86.6% from FY2014.

  • Gains from Sales and Divestitures has a five-year compound annual growth rate of -57.6% (FY2010 to FY2015).
  • By year, Gains from Sales and Divestitures came in at $838,000 in FY2014 and $2.25 million in FY2011 (-72.5%).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Exelixis 14.53 Bn 10.87 Bn 608.03 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2016 2.49 Mn
Dec 31, 2015 17,000.00
Mar 31, 2015 95,000.00
Sep 30, 2014 838,000.00
Dec 31, 2011 44,000.00
Sep 30, 2011 2.21 Mn
API Access

Exelixis Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=EXEL&period=max&api_key=YOUR_API_KEY